Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder?
Arantza Sanvisens, Roberto Muga, Paola Zuluaga(Universitat Autònoma de Barcelona), Ferrán Bolao(Bellvitge University Hospital), Inmaculada Jarrín(Instituto de Salud Carlos III), Jordi Tor(Universitat Autònoma de Barcelona), Magı́ Farré(Universitat Autònoma de Barcelona), Álvaro Muñoz(Universidad de Guadalajara)
Cited by 6
Related Papers
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
|The Lancet|2002|1.1k
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|The Lancet HIV|2023|506
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy
|Annals of Internal Medicine|2020|342
Bioavailability of Sulforaphane from Two Broccoli Sprout Beverages: Results of a Short-term, Cross-over Clinical Trial in Qidong, China
|Cancer Prevention Research|2011|199
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
|Clinical Microbiology and Infection|2020|128